Angela Hassman

Angela Hassman is a seasoned clinical research leader with over 2 decades of experience in early-phase clinical trial operations. As Executive Director of Clinical Pharmacology at Fortrea, Angela holds global responsibilities for the oversight and strategic management of Phase I Clinical Research Units (CRUs), including sites in Madison, Dallas, and Daytona Beach in the USA, and Leeds, UK.

Her leadership spans a wide array of early-phase study types, including First-in-Human (FIH), Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), pharmacokinetics (PK), drug-drug interaction (DDI), and radiolabeled hAME studies. Angela is recognized for her operational excellence, deep scientific understanding, and commitment to delivering high-quality data and patient safety across Fortrea’s clinical pharmacology portfolio.

Angela’s contributions have been pivotal in establishing Fortrea as a global leader in clinical pharmacology services, supporting innovative drug development programs for biotech and pharmaceutical partners worldwide.